STUDY SEARCH RESULTS

1 study found for your search request:  6482-016

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
Condition: Neoplasm malignant
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT04976634
Status: Active, not recruiting




Copyright © 2026 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  Consumer Health Data Privacy Policy  Your Privacy Choices   Accessibility  U.S. Corporate Site